ArticleDiscover oncology2026
Association between ranitidine use and thyroid cancer based on FAERS and VigiAccess databases.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThe potential carcinogenic risk of ranitidine has sparked widespread controversy, and its relationship with thyroid cancer remains unclear. This study aimed to evaluate the disproportionality signal for thyroid cancer reporting associated with ranitidine by comprehensively utilizing the FDA Adverse Event Reporting System (FAERS) and VigiAccess databases.
methodsThe data were sourced from the FAERS database and the VigiAccess database. Initially, data mining and statistical analyses were performed on ranitidine-related thyroid cancer events within the FAERS database to detect and characterize disproportionality signals. Subsequently, the findings were further supplemented using the VigiAccess database to provide additional supportive evidence.
resultsA disproportionality signal was identified between ranitidine and thyroid cancer (ROR = 40.60, 95% CI: 38.80-42.49, P < 0.05), with VigiAccess providing supplementary corroboration. Time-to-onset analysis showed higher reporting frequency of thyroid cancer with longer ranitidine exposure duration.
conclusionDespite certain limitations, our findings indicate a disproportionality signal suggesting a potential association between ranitidine use and thyroid cancer reporting in pharmacovigilance databases. In light of these findings, the disproportionality signal suggests a potential risk requiring confirmation through prospective studies; pending such validation, clinicians should exercise caution when prescribing ranitidine for extended periods, with attention to thyroid monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.